Contact
searchSearch
HMP Global
Login

Melanoma Resource Center

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Stephanie Holland
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
From Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
Allison Casey
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
From Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Stephanie Holland
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
From Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Grace Taylor, MS, MA
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
Ellen Kurek
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost of Ipilimumab vs High-Dose Interferon for Melanoma
11/11/2021
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although,...
11/11/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab Among Patients With Metastatic Melanoma
10/29/2021
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world...
10/29/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Ipilimumab vs High-Dose Interferon for High-Risk Melanoma
10/26/2021
Marta Rybczynski
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that...
10/26/2021
Journal of Clinical Pathways
News
Real-World Evidence for Option Value of Ipilimumab in Metastatic Melanoma
10/21/2021
Janelle Bradley
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide...
10/21/2021
Journal of Clinical Pathways
Quiz
Quiz: Dermoscopic Structures and Patterns in Melanoma Detection
10/12/2021
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is...
10/12/2021
Journal of Clinical Pathways

Newsfeed

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Stephanie Holland
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
Allison Casey
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Stephanie Holland
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Grace Taylor, MS, MA
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
Ellen Kurek
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Ipilimumab vs High-Dose Interferon for High-Risk Melanoma
10/26/2021
Marta Rybczynski
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that...
10/26/2021
Journal of Clinical Pathways
News
Real-World Evidence for Option Value of Ipilimumab in Metastatic Melanoma
10/21/2021
Janelle Bradley
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide...
10/21/2021
Journal of Clinical Pathways
News
Dermoscopic Structures and Patterns Important for Accurately Detecting Melanoma
09/15/2021
Findings from a systematic review and meta-analysis support the diagnostic importance of dermoscopic structures associated with melanoma detection and highlight the importance of the overall pattern.
Findings from a systematic review and meta-analysis support the diagnostic importance of dermoscopic structures associated with melanoma detection and highlight the importance of the overall pattern.
Findings from a systematic...
09/15/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Therapies for BRAF-Mutant Melanoma
08/27/2021
Pembrolizumab is cost-effective for the treatment of BRAF-mutant stage III melanoma, but dabrafenib-trametinib is not, according to study findings.
Pembrolizumab is cost-effective for the treatment of BRAF-mutant stage III melanoma, but dabrafenib-trametinib is not, according to study findings.
Pembrolizumab is cost-effective...
08/27/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Therapy Among Medicare Patients With BRAF-Mutant Melanoma
08/05/2021
While dabrafenib–trametinib may offer incremental QALYs in patients with BRAF-mutant stage III melanoma, it is not considered a cost-effective regimen, according to study findings.
While dabrafenib–trametinib may offer incremental QALYs in patients with BRAF-mutant stage III melanoma, it is not considered a cost-effective regimen, according to study findings.
While dabrafenib–trametinib may...
08/05/2021
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
News
NRF2 Inhibition Emerges as a Promising Strategy to Halt Esophageal Cancer Spread
08/13/2025
Lisa Kuhns, PhD, MD
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a promising new target to combat the deadly spread of esophageal squamous cell carcinoma (ESCC) by focusing on a master regulatory protein called NRF2, according to a study published in Cancers.
Researchers have identified a...
08/13/2025
Journal of Clinical Pathways
News
Palliative Care Use Rose 24% in Medicare Cancer Decedents, but Disparities Persist
08/12/2025
Hannah Musick
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use among Medicare decedents with poor-prognosis cancers grew significantly between 2018 and 2023. The change is driven by outpatient services, telehealth, and advanced practice clinicians—yet older adults,...
Specialty palliative care use...
08/12/2025
Journal of Clinical Pathways
News
Perioperative Durvalumab-FLOT Regimen Demonstrates Superior Efficacy Over FLOT Alone
08/06/2025
Juliet Gallagher
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in the New England Journal of Medicine presents compelling evidence that perioperative durvalumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy significantly improves...
A new phase 3 study published in...
08/06/2025
Journal of Clinical Pathways
News
Specialized Teams Improve Safety as Immunotherapy Use Surges in Cancer Care
07/30/2025
Lisa Kuhns, PhD, MD
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to transform cancer treatment, multidisciplinary teams are proving essential for managing the potentially severe toxicities that accompany these therapies, according to an article published in the American Society...
As immunotherapy continues to...
07/30/2025
Journal of Clinical Pathways
News
NCCN Launches Interactive NCCN Guidelines Navigator to Advance Cancer Care Usability
07/11/2025
Grace Taylor, MS, MA
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National Comprehensive Cancer Network’s (NCCN) new digital Guidelines Navigator is transforming cancer care delivery with smarter, faster, and more accessible clinical guidelines.
Discover how the National...
07/11/2025
Journal of Clinical Pathways
News
Study Finds Key Risk Factors for Gastric Cancer in US Patients With Chronic Gastritis
07/11/2025
Lisa Kuhns, PhD, MD
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed with chronic atrophic gastritis (CAG) face a measurable risk of progressing to non-cardia gastric cancer (NCGC), with certain clinical and demographic factors significantly increasing that risk.
Adults under age 65 diagnosed...
07/11/2025
Journal of Clinical Pathways
News
Persistent Barriers in Gastric Cancer Care: GI Cancers Alliance Study
07/09/2025
Grace Taylor, MS, MA
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI Cancers Alliance reveals critical gaps in gastric cancer care, highlighting persistent disparities in biomarker access, patient education, and mental health support.
A year-long study by the GI...
07/09/2025
Journal of Clinical Pathways
News
Nivolumab-Based Regimens Extend Survival in Advanced Gastroesophageal Cancer Based on Molecular Biomarkers
06/25/2025
Lisa Kuhns, PhD, MD
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy shows promise in extending survival for patients with advanced gastroesophageal adenocarcinoma, particularly in those with specific molecular and genomic profiles, according to study results published in Nature...
Nivolumab-based immunotherapy...
06/25/2025
Journal of Clinical Pathways
News
Study Shows Improved Outcomes in Older Adults With Mantle Cell Lymphoma Following Adoption of New Therapies
06/16/2025
Juliet Gallagher
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large, retrospective cohort study using SEER-Medicare data highlight improvements in survival outcomes over time among older adults with mantle cell lymphoma (MCL), likely associated with the adoption of novel therapeutic...
New findings from a large,...
06/16/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost of Ipilimumab vs High-Dose Interferon for Melanoma
11/11/2021
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although,...
11/11/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab Among Patients With Metastatic Melanoma
10/29/2021
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world...
10/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Dermoscopic Structures and Patterns in Melanoma Detection
10/12/2021
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is...
10/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Pembrolizumab for the Treatment of BRAF-Mutant Stage III Melanoma
09/07/2021
True or False: For the treatment of BRAF-mutant stage III melanoma, pembrolizumab is most cost-effective at a conventional willingness-to-pay threshold.
True or False: For the treatment of BRAF-mutant stage III melanoma, pembrolizumab is most cost-effective at a conventional willingness-to-pay threshold.
True or False: For the treatment...
09/07/2021
Journal of Clinical Pathways
Quiz
Quiz: Dabrafenib–Trametinib for Treating Melanoma
08/23/2021
True or False: Dabrafenib–trametinib offers incremental quality-adjusted life years in patients with BRAF-mutant stage III melanoma, but it is not considered cost-effective.
True or False: Dabrafenib–trametinib offers incremental quality-adjusted life years in patients with BRAF-mutant stage III melanoma, but it is not considered cost-effective.
True or False:...
08/23/2021
Journal of Clinical Pathways
Quiz
Quiz: First-Year Costs Among Patients With Melanoma
08/18/2021
08/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Adverse Event Costs Among Patients With Metastatic Melanoma
07/20/2021
True or False: Costs associated with adverse events among patients with metastatic melanoma are small, encompassing only 3% of total costs.
True or False: Costs associated with adverse events among patients with metastatic melanoma are small, encompassing only 3% of total costs.
True or False: Costs associated...
07/20/2021
Journal of Clinical Pathways
Quiz
Quiz: Immune Checkpoint Inhibitors (ICIs) in Cutaneous Metastatic Melanoma
03/10/2021
03/10/2021
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use